Shionogi & Co Ltd 2023 Integrated Report
The report presents SHIONOGI's 2030 Vision as combining a growing global healthcare business, solutions to social health issues, and highly capable employees. It reports FY2022 revenue of ¥426.7 billion and highlights progress in COVID-19 treatments, the HIV franchise, and expansion beyond prescription drugs. It also frames ESG management and human-capital development as foundations for sustainable growth.
Company: Shionogi & Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2023
Type: Integrated Report
Pages: 40
Back to company
Shionogi & Co Ltd
Integrated Report
The report presents SHIONOGI's 2030 Vision as combining a growing global healthcare business, solutions to social health issues, and highly capable employees. It reports FY2022 revenue of ¥426.7 billion and highlights progress in COVID-19 treatments, the HIV franchise, and expansion beyond prescription drugs. It also frames ESG management and human-capital development as foundations for sustainable growth.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2022
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management